Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D den Brok

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Breast Cancer Research and Treatment|December 22, 2016
Survival with metastatic breast cancer based on initial presentation, de novo versus relapsedWendie D den Brok, Caroline H Speers, Lovedeep Gondara, et al.
Breast Cancer Research and Treatment|January 23, 2017
Response to "Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?"Wendie D den Brok, Caroline H Speers, Lovedeep Gondara, et al.
JCO Precision Oncology|February 17, 2022
Homologous Recombination Deficiency in Breast Cancer: A Clinical ReviewWendie D den Brok, Kasmintan A Schrader, Sophie Sun, et al.
Scientific Reports|January 19, 2021
Super-resolution time-resolved imaging using computational sensor fusionC Callenberg, A Lyons, D den Brok, et al.
Blood Advances|August 1, 2020
Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphomaDiego Villa, Laurie H Sehn, Kerry J Savage, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Breast Cancer Research and Treatment|December 22, 2016
Survival with metastatic breast cancer based on initial presentation, de novo versus relapsedWendie D den Brok, Caroline H Speers, Lovedeep Gondara, et al.
Breast Cancer Research and Treatment|January 23, 2017
Response to "Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?"Wendie D den Brok, Caroline H Speers, Lovedeep Gondara, et al.
JCO Precision Oncology|February 17, 2022
Homologous Recombination Deficiency in Breast Cancer: A Clinical ReviewWendie D den Brok, Kasmintan A Schrader, Sophie Sun, et al.
Scientific Reports|January 19, 2021
Super-resolution time-resolved imaging using computational sensor fusionC Callenberg, A Lyons, D den Brok, et al.
Blood Advances|August 1, 2020
Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphomaDiego Villa, Laurie H Sehn, Kerry J Savage, et al.
Pageof 1